B. Riley restated their buy rating on shares of Joint (NASDAQ:JYNT) in a research report sent to investors on Friday morning, Stock Target Advisor reports. They currently have a $25.00 target price on the stock. B. Riley also issued estimates for Joint’s FY2021 earnings at $0.42 EPS.

A number of other equities analysts have also recently issued reports on the company. DA Davidson boosted their price objective on Joint from $23.00 to $32.00 and gave the company a buy rating in a report on Tuesday, November 12th. Maxim Group restated a buy rating and set a $25.00 price objective on shares of Joint in a report on Friday, November 8th. ValuEngine cut Joint from a buy rating to a hold rating in a report on Wednesday, October 2nd. BidaskClub cut Joint from a buy rating to a hold rating in a report on Saturday, December 7th. Finally, TheStreet cut Joint from a b- rating to a c rating in a report on Monday, January 6th. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus price target of $25.50.

Shares of Joint stock opened at $16.28 on Friday. The stock has a 50 day moving average price of $17.12 and a 200-day moving average price of $18.17. Joint has a one year low of $7.89 and a one year high of $21.80. The company has a debt-to-equity ratio of 3.11, a quick ratio of 0.84 and a current ratio of 0.84. The stock has a market cap of $221.81 million, a price-to-earnings ratio of 80.00 and a beta of 0.93.

Joint (NASDAQ:JYNT) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.04 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.03 by $0.01. Joint had a return on equity of 104.54% and a net margin of 6.57%. The company had revenue of $12.73 million during the quarter, compared to analysts’ expectations of $11.60 million. Sell-side analysts predict that Joint will post 0.21 earnings per share for the current fiscal year.

In other Joint news, Director Glenn J. Krevlin sold 100,000 shares of Joint stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $17.76, for a total transaction of $1,776,000.00. Following the completion of the sale, the director now directly owns 2,500 shares of the company’s stock, valued at approximately $44,400. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 6.10% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of JYNT. BlackRock Inc. raised its position in Joint by 1,224.0% during the 2nd quarter. BlackRock Inc. now owns 769,378 shares of the company’s stock valued at $14,002,000 after purchasing an additional 711,267 shares in the last quarter. Sanders Morris Harris LLC bought a new stake in Joint during the 4th quarter valued at $10,174,000. Morgan Stanley raised its position in Joint by 1,673.2% during the 2nd quarter. Morgan Stanley now owns 183,772 shares of the company’s stock valued at $3,344,000 after purchasing an additional 173,408 shares in the last quarter. Vanguard Group Inc. raised its position in Joint by 42.0% during the 2nd quarter. Vanguard Group Inc. now owns 538,070 shares of the company’s stock valued at $9,793,000 after purchasing an additional 159,034 shares in the last quarter. Finally, Cadence Capital Management LLC bought a new stake in Joint during the 3rd quarter valued at $2,815,000. 67.44% of the stock is owned by institutional investors and hedge funds.

Joint Company Profile

The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics. The company operates through two segments, Corporate Clinics and Franchise Operations. It operates through direct ownership, management arrangements, franchising, and the sale of regional developer rights. As of March 07, 2019, the company operated 450 clinics in the United States.

Recommended Story: Beige Book

Analyst Recommendations for Joint (NASDAQ:JYNT)

Receive News & Ratings for Joint Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Joint and related companies with MarketBeat.com's FREE daily email newsletter.